Top-Rated StocksTop-RatedNASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis $67.25 +0.31 (+0.46%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$67.27 +0.02 (+0.03%) As of 08/15/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Merus Stock (NASDAQ:MRUS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Merus alerts:Sign Up Key Stats Today's Range$66.35▼$67.4550-Day Range$52.33▼$67.4552-Week Range$33.19▼$67.59Volume338,220 shsAverage Volume644,751 shsMarket Capitalization$5.09 billionP/E RatioN/ADividend YieldN/APrice Target$88.50Consensus RatingBuy Company Overview Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Read More Merus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreMRUS MarketRank™: Merus scored higher than 39% of companies evaluated by MarketBeat, and ranked 1391st out of 1,876 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMerus has only been the subject of 3 research reports in the past 90 days.Read more about Merus' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($3.85) to ($4.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -12.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -12.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 7.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Merus' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.44% of the float of Merus has been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Merus has recently increased by 3.30%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.44% of the float of Merus has been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Merus has recently increased by 3.30%, indicating that investor sentiment is decreasing. News and Social Media1.9 / 5News Sentiment0.37 News SentimentMerus has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Merus this week, compared to 7 articles on an average week.Search Interest4 people have searched for MRUS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Merus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Merus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,586,340.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of Merus is held by insiders.Percentage Held by Institutions96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Merus' insider trading history. Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address MRUS Stock News HeadlinesMerus N.V. (NASDAQ:MRUS) COO Peter B. Silverman Sells 25,000 SharesJuly 19, 2025 | insidertrades.comHC Wainwright Comments on Merus' Q3 Earnings (NASDAQ:MRUS)August 12, 2025 | americanbankingnews.comGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly income to cover housing, healthcare, food, and fun... With a fraction of what you probably think you need. | Investors Alley (Ad)Merus N.V. (NASDAQ:MRUS) Receives Average Rating of "Buy" from BrokeragesAugust 10, 2025 | americanbankingnews.comWilliam Blair Issues Pessimistic Outlook for Merus EarningsAugust 10, 2025 | americanbankingnews.comWe Think Merus (NASDAQ:MRUS) Can Afford To Drive Business GrowthAugust 7, 2025 | finance.yahoo.comMerus to Present at the Canaccord Genuity 45th Annual Growth ConferenceAugust 6, 2025 | globenewswire.comMerus Announces Financial Results for the Second Quarter 2025 and Provides Business UpdateAugust 5, 2025 | globenewswire.comSee More Headlines MRUS Stock Analysis - Frequently Asked Questions How have MRUS shares performed this year? Merus' stock was trading at $42.05 at the beginning of 2025. Since then, MRUS shares have increased by 59.9% and is now trading at $67.25. How were Merus' earnings last quarter? Merus N.V. (NASDAQ:MRUS) posted its earnings results on Tuesday, August, 5th. The biotechnology company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($1.17) by $1.06. The biotechnology company earned $8.83 million during the quarter, compared to the consensus estimate of $9.77 million. Merus had a negative trailing twelve-month return on equity of 50.28% and a negative net margin of 685.64%. When did Merus IPO? Merus (MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. Who are Merus' major shareholders? Top institutional investors of Merus include Commodore Capital LP (4.66%), Holocene Advisors LP (2.94%), Westfield Capital Management Co. LP (2.70%) and Franklin Resources Inc. (2.43%). Insiders that own company stock include Sven Ante Lundberg, Harry Shuman and Peter B Silverman. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE), Jabil (JBL) and Disc Medicine (IRON). Company Calendar Last Earnings8/05/2025Today8/17/2025Next Earnings (Estimated)10/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRUS CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees37Year Founded2003Price Target and Rating Average Price Target for Merus$88.50 High Price Target$110.00 Low Price Target$70.00 Potential Upside/Downside+31.6%Consensus RatingBuy Rating Score (0-4)3.09 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($5.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$215.33 million Net Margins-685.64% Pretax Margin-670.59% Return on Equity-50.28% Return on Assets-42.00% Debt Debt-to-Equity RatioN/A Current Ratio8.39 Quick Ratio8.39 Sales & Book Value Annual Sales$36.13 million Price / Sales140.77 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book7.11Miscellaneous Outstanding Shares75,630,000Free Float72,836,000Market Cap$5.09 billion OptionableOptionable Beta1.09 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:MRUS) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.